From the Department of Health Systems and Population Health, University of Washington School of Public Health, Seattle, WA (MCF); Health Systems Research (HSR) Center of Innovation for Veteran-Centered and Value-Driven Care, VA Puget Sound Health Care System, Seattle, WA (MCF); Michigan Innovations in Addiction Care through Research & Education (MI-ACRE), Addiction Center, Department of Psychiatry, University of Michigan, Ann Arbor, MI (LNC, LZ, LAL); and VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, MI 48105 (LZ, LAL).
J Addict Med. 2024;18(5):561-566. doi: 10.1097/ADM.0000000000001329. Epub 2024 Jun 3.
Stimulant use is a growing problem, but little is known about service utilization among patients with stimulant use disorder (StUD). In the context of the overdose crisis, much research has focused on patients with opioid use disorder (OUD). It is unclear how the characteristics, treatment receipt, and hospitalization of patients with StUD differ from patients with OUD.
Electronic health record data were extracted for national Veterans Health Administration patients with a visit from March 1, 2020, to February 28, 2021 with StUD and/or OUD (N = 132,273). We compared patients with StUD without OUD to those with (1) co-occurring StUD + OUD and (2) OUD without StUD. Patient characteristics, substance use disorder treatment, and hospitalizations in the year following patients' first study period visit were descriptively compared. Treatment and hospitalization were also compared in adjusted regression models.
Compared with patients with OUD + StUD, those with StUD without OUD were less likely to receive outpatient (adjusted odds ratio [aOR] 0.49, 95% confidence interval [CI] 0.47-0.50) or any treatment (aOR 0.47, 95% CI 0.46-0.49). Compared with patients with OUD without StUD, those with StUD without OUD were less likely to receive outpatient (aOR 0.51, 95% CI 0.49-0.52) or any treatment (aOR 0.56, 95% CI 0.54-0.58) and more likely to receive residential treatment (aOR 2.18, 95% 2.05-2.30) and to be hospitalized (aOR 1.62, 95% 1.56-1.69).
Patients with StUD may be less likely to receive treatment and more likely to be hospitalized than patients with OUD. Efforts focused on mitigating hospitalization and increasing treatment receipt for patients with StUD are needed.
兴奋剂的使用是一个日益严重的问题,但人们对兴奋剂使用障碍(StUD)患者的服务利用情况知之甚少。在过量危机的背景下,大量研究集中在阿片类药物使用障碍(OUD)患者身上。目前尚不清楚 StUD 患者的特征、治疗接受情况和住院情况与 OUD 患者有何不同。
从 2020 年 3 月 1 日至 2021 年 2 月 28 日,从全国退伍军人健康管理局的电子健康记录中提取有 StUD 和/或 OUD 就诊的患者数据(N=132273)。我们比较了无 OUD 的 StUD 患者与(1)同时存在 StUD+OUD 和(2)无 StUD 的 OUD 患者。描述性比较了患者在首次研究期就诊后一年的物质使用障碍治疗和住院情况。还在调整后的回归模型中比较了治疗和住院情况。
与 OUD+StUD 患者相比,无 OUD 的 StUD 患者接受门诊治疗(调整后的优势比[aOR]0.49,95%置信区间[CI]0.47-0.50)或任何治疗(aOR 0.47,95%CI 0.46-0.49)的可能性较小。与无 StUD 的 OUD 患者相比,无 OUD 的 StUD 患者接受门诊治疗(aOR 0.51,95%CI 0.49-0.52)或任何治疗(aOR 0.56,95%CI 0.54-0.58)的可能性较小,接受住院治疗(aOR 2.18,95%CI 2.05-2.30)和住院的可能性较大(aOR 1.62,95%CI 1.56-1.69)。
与 OUD 患者相比,StUD 患者接受治疗的可能性较小,住院的可能性较大。需要努力减少 StUD 患者的住院治疗并增加治疗的接受程度。